A New Cardiac Rehabilitation Treatment in the Application of Ischemic Heart Disease

NCT06681506 · tracked via the Priya Life Science China tracker

Sponsor

Shanghai 10th People's Hospital

Phase

Not applicable

Started

2024-01-01

Last updated

2024-11-08

Condition(s) studied

Ischemic Heart DiseaseCardiac Rehabilitation

Investigational drug(s) / intervention(s)

Metronomic breathing, exercise rehabilitation, external counterpulsation, extracorporeal shock wave.bedside rehabilitation and breathing, balance, flexibility, movement rehabilitation

Metronomic breathing, exercise rehabilitation, external counterpulsation, extracorporeal shock wave.: Phase I rehabilitation(Metronomic breathing，exercise rehabilitation）,Phase II rehabilitation (exercise rehabilitation, external counterpulsation, extracorporeal shock) wave.)

bedside rehabilitation and breathing, balance, flexibility, movement rehabilitation: Phase I rehabilitation (bedside rehabilitation, breathing rehabilitation), Phase II rehabilitation (breathing, balance, flexibility, movement)

Study summary

Cardiac rehabilitation is an important link in cardiovascular disease. This study mainly explores the effectiveness of new cardiac rehabilitation therapy (early respiratory rehabilitation, phase I rehabilitation, exercise therapy, external counterpulsation, extracorporeal shock wave, etc.) on patients with ischemic heart disease such as coronary heart disease and heart failure, and the compliance of home rehabilitation compared with traditional cardiac rehabilitation therapy (traditional exercise rehabilitation, rehabilitation education, etc.).

Eligibility

Sex

ALL

Min age

18 Years

Max age

85 Years

Healthy volunteers

Inclusion Criteria: * Aged between 18 and 85 years old * Female subjects no pregnancy * The main admission diagnosis of ischemic heart disease (coronary heart disease, myocardial infarction, ischemic heart failure, etc.) * The need for cardiac rehabilitation treatment Exclusion Criteria: * acute respiratory distress syndrome (ARDS); * acute episode of COPD; * uncontrolled pulmonary infection; * acute heart failure; acute pulmonary embolism; * acute myocarditis/pericarditis; * severe arrhythmia (degree II or III atrioventricular block, atrial flutter, or atrial fibrillation); * sternotomy, rib fracture, thoracic deformity, or other neurological diseases that may affect respiratory muscles

Primary outcome measure(s)

Change from baseline myocardial infarct area at 6 months — 1 day of inclusions and 6 months after the first treatment.
The location and extent of myocardial infarction were determined by D-SPECT.

Trial sites (1)

Facility	City	Region	Status
Department of Cardiology, Shanghai Tenth People's Hospital	Shanghai	Shanghai Municipality	Recruiting

More Shanghai 10th People's Hospital trials in China

Evaluating the Diagnostic Performance and Impact on Clinical Outcomes of the NuRapid-CRISPR Pathogen Profile Assay in ICU Patients With Sepsis Starting soon

Assessment and Digital-health Based Intervention on Subclinical Organ Damage and Cardiovascular Risk in Chinese Starting soon

AI-Empowered Fundus Platform Recruiting

The Impact of Atrial Pressure Change Before and After Combined Procedure Recruiting

BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction Recruiting

Other trials for the same condition

Effects of Enhanced External Counterpulsation Combined With Cardiac Rehabilitation in Patients With Atrial Fibrillation Starting soon

RESOLUTE ONYX China Single Arm Study Active, not recruiting

Registry of Multicenter Brain-Heart Comorbidity in China Recruiting

Functional ComprEhensive AssessmenT by IVUS Reconstruction in Patients With Suspected IschEmic Heart Disease (FEATURE) Active, not recruiting

Chaigui Longmu Ejiao Paste for Ischemic Heart Disease Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06681506 on ClinicalTrials.gov ↗ ← All trials in China